Information Services Group (III) Given a $6.00 Price Target at Barrington Research

Vanguard Group Inc. lifted its holdings in Information Services Group by 0.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,743,298 shares of the business services provider’s stock valued at $7,165,000 after purchasing an additional 5,181 shares during the last quarter. Dimensional Fund …

Information Services Group, Inc. logoBarrington Research set a $6.00 price target on Information Services Group (NASDAQ:III) in a report released on Tuesday. The brokerage currently has a buy rating on the business services provider’s stock.

III has been the subject of several other research reports. Noble Financial reissued a buy rating on shares of Information Services Group in a report on Friday, March 16th. Zacks Investment Research downgraded Information Services Group from a hold rating to a sell rating in a report on Tuesday, January 9th. Finally, B. Riley reissued a buy rating on shares of Information Services Group in a report on Tuesday, March 13th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $5.67.

Shares of Information Services Group (III) opened at $4.12 on Tuesday. The company has a market capitalization of $185.23, a P/E ratio of -82.40, a PEG ratio of 1.36 and a beta of 0.42. The company has a quick ratio of 1.89, a current ratio of 1.89 and a debt-to-equity ratio of 1.58. Information Services Group has a twelve month low of $2.95 and a twelve month high of $4.63.

A number of institutional investors have recently made changes to their positions in III. Northern Trust Corp lifted its holdings in Information Services Group by 5.4% during the 2nd quarter. Northern Trust Corp now owns 381,784 shares of the business services provider’s stock valued at $1,569,000 after purchasing an additional 19,660 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Information Services Group by 0.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,743,298 shares of the business services provider’s stock valued at $7,165,000 after purchasing an additional 5,181 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in Information Services Group during the 2nd quarter valued at $188,000. State Street Corp lifted its holdings in Information Services Group by 9.1% during the 2nd quarter. State Street Corp now owns 462,199 shares of the business services provider’s stock valued at $1,899,000 after purchasing an additional 38,369 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Information Services Group by 76.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,849 shares of the business services provider’s stock valued at $114,000 after purchasing an additional 12,098 shares during the last quarter. 45.11% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Information Services Group (III) Given a $6.00 Price Target at Barrington Research” was reported by Macon Daily and is owned by of Macon Daily. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://macondaily.com/2018/03/21/information-services-group-iii-given-a-6-00-price-target-at-barrington-research.html.

Information Services Group Company Profile

Information Services Group, Inc is a technology insights, market intelligence and advisory services company. The Company operates in the segment of fact-based sourcing advisory services. It supports private and public sector organizations to transform and optimize their operational environments through research, benchmarking, consulting and managed services with a focus on information technology, business process transformation, program management services and enterprise resource planning.

Receive News & Ratings for Information Services Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Information Services Group and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Vanguard Group Inc is the third biggest owner of Arena Pharmaceuticals, Inc. (ARNA)

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) enjoyed a 251.77% run-up in share price since hitting record low of $11.30. The stock managed 28.68% rise and now stands at $39.75 as of 03/20/2018. At recent session, the prices were hovering between $38.96 and $44.44. This company shares are …

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) enjoyed a 251.77% run-up in share price since hitting record low of $11.30. The stock managed 28.68% rise and now stands at $39.75 as of 03/20/2018. At recent session, the prices were hovering between $38.96 and $44.44. This company shares are 29.74% off its target price of $51.57 and the current market capitalization stands at $1.63B. The recent change has given its price a 3.07% lead over SMA 50 and -10.67% deficit over its 52-week high. The stock witnessed -2.57% declines, 31.49% gains and 63.51% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ARNA’s volatility during a week at 11.26% and during a month it has been found around 6.68%.

Arena Pharmaceuticals, Inc. (ARNA) Top Holders

Institutional investors currently hold around $889 million or 74.6% in ARNA stock. Look at its top three institutional owners. Wellington Management Group Llp owns $111.49 million in Arena Pharmaceuticals, Inc., which represents roughly 6.84% of the company’s market cap and approximately 12.54% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 3,214,616 shares of the stock are valued at $99.3 million. The third largest holder is Vanguard Group Inc, which currently holds $98.99 million worth of this stock and that ownership represents nearly 6.07% of its market capitalization.

Arena Pharmaceuticals, Inc. 13F Filings

At the end of 12/31/2017 reporting period, 70 institutional holders increased their position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by some 3,213,911 shares, 59 decreased positions by 3,171,570 and 15 held positions by 22,408,707. That puts total institutional holdings at 28,794,188 shares, according to SEC filings. The stock grabbed 24 new institutional investments totaling 1,073,758 shares while 20 institutional investors sold out their entire positions totaling 842,650 shares.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Insider Trades

Multiple company employees have indulged in significant insider trading. Arena Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President and CEO Munshi Amit has acquired 2,500 shares of Arena Pharmaceuticals, Inc. (ARNA) in trading session dated May. 12, 2017. These shares are worth $29,750 and were traded at $11.9 each. The SEC filing shows that Munshi Amit performed a purchase of 5,000 shares. The President and CEO added these shares by way of transaction on Apr. 26, 2017. The company’s shares were assimilated at $14.1 per share worth to an investment of some $70,500 on account of Munshi Amit.

Director, White Christine Anna, sold 1,873 common shares of Arena Pharmaceuticals, Inc. (ARNA) in the open market. In a transaction dated Jun. 13, 2016, the shares were put up for sale at an average price of $19.9, raking in a sum of $37,273. After this sale, 8,553 common shares of ARNA are directly owned by the insider, with total stake valued at $339,982.

In the transaction dated Mar. 30, 2015, the great number of shares disposed came courtesy the Director; Woods Randall E disposed a total of 7,627 shares at an average price of $44.9, amounting to approximately $342,452. The insider now directly owns 4,511 shares worth $179,312.

Arena Pharmaceuticals, Inc. (ARNA) Analyst Guide

Several analysts have released their opinion on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), with 5 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.33 average brokerage recommendation.

Related Posts:

Cormorant Asset Management, Llc is the second biggest holder of Proteostasis Therapeutics, Inc …

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) is on recovery track with 265.96% gain from a 1-year low price of $1.41. The company lost -26.18% to attain the price of $5.16 on 03/20/2018. Throughout the recent session, the prices were hovering between $4.98 and $6.14. These shares are 210.08% off …

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) is on recovery track with 265.96% gain from a 1-year low price of $1.41. The company lost -26.18% to attain the price of $5.16 on 03/20/2018. Throughout the recent session, the prices were hovering between $4.98 and $6.14. These shares are 210.08% off its target price of $16 and the current market capitalization stands at $165.89M. The recent change has given its price a 26.44% lead over SMA 50 and -60.79% deficit over its 52-week high. The stock witnessed 77.93% gains, 3.41% gains and 174.47% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PTI’s volatility during a week at 16.36% and during a month it has been found around 11.4%.

Proteostasis Therapeutics, Inc. (PTI) Top Holders

Institutional investors currently hold around $163 million or 72.2% in PTI stock. Look at its top three institutional owners. Nea Management Company, Llc owns $38.84 million in Proteostasis Therapeutics, Inc., which represents roughly 23.41% of the company’s market cap and approximately 23.83% of the institutional ownership. Similar statistics are true for the second largest owner, Cormorant Asset Management, Llc, which owns 3,300,000 shares of the stock are valued at $23.07 million. The third largest holder is Jennison Associates Llc, which currently holds $22.22 million worth of this stock and that ownership represents nearly 13.39% of its market capitalization.

Proteostasis Therapeutics, Inc. 13F Filings

At the end of 12/31/2017 reporting period, 29 institutional holders increased their position in Proteostasis Therapeutics, Inc. (NASDAQ:PTI) by some 8,985,418 shares, 21 decreased positions by 2,799,016 and 8 held positions by 11,552,492. That puts total institutional holdings at 23,336,926 shares, according to SEC filings. The stock grabbed 18 new institutional investments totaling 3,852,660 shares while 5 institutional investors sold out their entire positions totaling 363,492 shares.

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Insider Trades

Multiple company employees have indulged in significant insider trading. Proteostasis Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Berger Franklin M has acquired 60,000 shares of Proteostasis Therapeutics, Inc. (PTI) in trading session dated Dec. 18, 2017. These shares are worth $300,000 and were traded at $5 each. The SEC filing shows that Kelly Jeffery W. performed a purchase of 4,000 shares. The Director added these shares by way of transaction on Dec. 18, 2017. The company’s shares were assimilated at $5 per share worth to an investment of some $20,000 on account of Kelly Jeffery W..

President and CEO, Chhabra Meenu, purchased 40,000 common shares of Proteostasis Therapeutics, Inc. (PTI) in the open market. In a transaction dated Dec. 18, 2017, the shares were bought at an average price of $5, giving away a sum of $200,000. After this purchase, 50,218 common shares of PTI are directly owned by the insider, with total stake valued at $259,125.

In the transaction dated Dec. 18, 2017, the great number of shares acquired came courtesy the 10% Owner; New Enterprise Associates 12, added a total of 2,000,000 shares at an average price of $5, amounting to approximately $10,000,000. The insider now directly owns 5,554,610 shares worth $28,661,788.

Proteostasis Therapeutics, Inc. (PTI) Analyst Guide

Several analysts have released their opinion on Proteostasis Therapeutics, Inc. (NASDAQ:PTI), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.33 average brokerage recommendation.

Related Posts:

Kohlberg Kravis Roberts & Co. LP built an about 72.32% stake in Willbros Group, Inc. (WG)

Kohlberg Kravis Roberts & Co. L.P. owns $8.51 million in Willbros Group, Inc., which represents roughly 72.32% of the company’s market cap and approximately 26.58% of the institutional ownership. Similar statistics are true for the second largest owner, Gendell Jeffrey L, which owns 4,250,094 shares …

Willbros Group, Inc. (NYSE:WG) is now up -76.43% compared to a 12-month low of $0.80. We have seen the price to move -77.52% lower and get settled at $0.19 on 03/20/2018. At recent session, it appeared stuck in a range of $0.1725 to $0.75. This company shares are 426.32% off its target price of $1 and the current market capitalization stands at $11.76M. The recent change has given its price a -82.09% deficit over SMA 50 and -94.37% deficit over its 52-week high. The stock witnessed -80.73% declines, -84.65% declines and -93.53% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found WG’s volatility during a week at 72.38% and during a month it has been found around 22.46%.

Willbros Group, Inc. (WG) Top Holders

Institutional investors currently hold around $32 million or 65.8% in WG stock. Look at its top three institutional owners. Kohlberg Kravis Roberts & Co. L.P. owns $8.51 million in Willbros Group, Inc., which represents roughly 72.32% of the company’s market cap and approximately 26.58% of the institutional ownership. Similar statistics are true for the second largest owner, Gendell Jeffrey L, which owns 4,250,094 shares of the stock are valued at $3.57 million. The third largest holder is Blackrock Inc., which currently holds $2.77 million worth of this stock and that ownership represents nearly 23.54% of its market capitalization.

Willbros Group, Inc. 13F Filings

At the end of 12/31/2017 reporting period, 37 institutional holders increased their position in Willbros Group, Inc. (NYSE:WG) by some 3,189,459 shares, 48 decreased positions by 7,099,408 and 18 held positions by 28,080,161. That puts total institutional holdings at 38,369,028 shares, according to SEC filings. The stock grabbed 10 new institutional investments totaling 512,156 shares while 19 institutional investors sold out their entire positions totaling 1,062,275 shares.

Willbros Group, Inc. (NYSE:WG) Insider Trades

Multiple company employees have indulged in significant insider trading. Willbros Group, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that EVP, Utility T&D Johnny Priest has acquired 20,000 shares of Willbros Group, Inc. (WG) in trading session dated Nov. 15, 2017. These shares are worth $23,200 and were traded at $1.16 each. The SEC filing shows that Fournier Michael J performed a purchase of 42,500 shares. The President & COO added these shares by way of transaction on Nov. 20, 2015. The company’s shares were assimilated at $2.56 per share worth to an investment of some $108,800 on account of Fournier Michael J.

Director, Williams S Miller, purchased 10,000 common shares of Willbros Group, Inc. (WG) in the open market. In a transaction dated Nov. 19, 2015, the shares were bought at an average price of $2.61, giving away a sum of $26,100. After this purchase, 101,726 common shares of WG are directly owned by the insider, with total stake valued at $19,328.

In the transaction dated Nov. 18, 2015, the great number of shares acquired came courtesy the EVP, Utility T&D; Johnny Priest added a total of 5,000 shares at an average price of $2.48, amounting to approximately $12,400. The insider now directly owns 188,584 shares worth $35,831.

Related Posts:

Want To Invest In Artificial Intelligence SA. (WSE:ARN)? Here’s How It Performed Lately

Investors with a long-term horizong may find it valuable to assess Artificial Intelligence SA.’s (WSE:ARN) earnings trend over time and against its industry benchmark as opposed to simply looking at a sincle earnings announcement at one point in time. Below is my commentary, albiet very simple and …

Investors with a long-term horizong may find it valuable to assess Artificial Intelligence SA.’s (WSE:ARN) earnings trend over time and against its industry benchmark as opposed to simply looking at a sincle earnings announcement at one point in time. Below is my commentary, albiet very simple and high-level, on how Artificial Intelligence is currently performing. Check out our latest analysis for Artificial Intelligence

How Did ARN’s Recent Performance Stack Up Against Its Past?

For the most up-to-date info, I use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. This technique allows me to examine different companies in a uniform manner using the most relevant data points. For Artificial Intelligence, its most recent trailing-twelve-month earnings is -ZŁ9.64M, which, in comparison to last year’s level, has become more negative. Since these values may be fairly short-term, I have created an annualized five-year value for ARN’s net income, which stands at -ZŁ1.34M. This doesn’t seem to paint a better picture, since earnings seem to have gradually been getting more and more negative over time.

WSE:ARN Income Statement Mar 21st 18
WSE:ARN Income Statement Mar 21st 18

We can further examine Artificial Intelligence’s loss by looking at what the industry has been experiencing over the past few years. Each year, for the last five years Artificial Intelligence’s revenue growth has been fairly soft, with an annual growth rate of 0.74%, on average. The company’s inability to breakeven has been aided by the relatively flat top-line in the past. Viewing growth from a sector-level, the PL internet industry has been growing its average earnings by double-digit 13.58% over the previous twelve months, and 20.19% over the previous five years. This means whatever tailwind the industry is benefiting from, Artificial Intelligence has not been able to gain as much as its average peer.

What does this mean?

While past data is useful, it doesn’t tell the whole story. Companies that incur net loss is always difficult to envisage what will occur going forward, and when. The most valuable step is to examine company-specific issues Artificial Intelligence may be facing and whether management guidance has consistently been met in the past. I suggest you continue to research Artificial Intelligence to get a more holistic view of the stock by looking at:

  • 1. Financial Health: Is ARN’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
  • 2. Valuation: What is ARN worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether ARN is currently mispriced by the market.
  • 3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

NB: Figures in this article are calculated using data from the trailing twelve months from 30 September 2017. This may not be consistent with full year annual report figures.

The easiest way to discover new investment ideas

Save hours of research when discovering your next investment with Simply Wall St. Looking for companies potentially undervalued based on their future cash flows? Or maybe you’re looking for sustainable dividend payers or high growth potential stocks. Customise your search to easily find new investment opportunities that match your investment goals. And the best thing about it? It’s FREE. Click here to learn more.

Related Posts: